Aurora Financial Journal

Organon & Co. (OGN)

NYSE · Health care · Pharmaceutical Preparations · Financial statements, TTM figures and earnings dates

Organon & Co. reported revenue of $6.13B over the trailing twelve months ended June 30, 2026, with net income of $209.0M. Annual financial statements are available for fiscal years 2019 to 2025, taken from the company's filings with the SEC. The next quarterly results release is estimated for November 9, 2026, based on the company's filing history.

Open interactive financials →

Key financials

USDTTM
2026-06-30
FY2025
2025-12-31
FY2024
2024-12-31
FY2023
2023-12-31
FY2022
2022-12-31
FY2021
2021-12-31
Income statement
Revenue$6.13B$6.22B$6.40B$6.26B$6.17B$6.30B
Gross profit$3.23B$3.31B$3.71B$3.75B$3.88B$3.92B
Operating income$959.0M$929.0M$1.33B$1.20B$1.54B$1.79B
Net income$209.0M$187.0M$864.0M$1.02B$917.0M$1.35B
Diluted EPS$0.78$0.72$3.33$3.99$3.59$5.31
Cash flow
Operating cash flow$737.0M$700.0M$939.0M$799.0M$858.0M$2.16B
Capital expenditure$170.0M$162.0M$175.0M$251.0M$196.0M$192.0M
Free cash flow$567.0M$538.0M$764.0M$548.0M$662.0M$1.97B
Balance sheet
Cash and equivalents$1.13B$574.0M$675.0M$693.0M$706.0M$737.0M
Total assets$13.18B$12.87B$13.10B$12.06B$10.96B$10.68B
Total liabilities$12.17B$12.12B$12.63B$12.13B$11.85B$12.19B
Total debt$8.55B$8.64B$8.88B$8.76B$8.91B$9.13B
Shareholders' equity$1.01B$752.0M$472.0M−$70.0M−$892.0M−$1.51B

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in USD as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full OGN page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open OGN financials →